Clinical trials for Achondroplasia
18 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGNCT07388966Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal DysplasiaSYSNAV · PI: Genevieve Baujat
- RECRUITINGPHASE2, PHASE3NCT07441876A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaBioMarin Pharmaceutical · PI: Medical Director, PhD
- RECRUITINGPhase 2NCT07169279Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)QED Therapeutics, a BridgeBio company
- RECRUITINGNCT07301463A Study in Children With AchondroplasiaAbbisko Therapeutics Co, Ltd · PI: Yuan Lu
- RECRUITINGPhase 2NCT06842355A Study of TYRA-300 in Children With Achondroplasia: BEACH301Tyra Biosciences, Inc · PI: Doug Warner, MD
- RECRUITINGPhase 2NCT06732895A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Ascendis Pharma A/S · PI: Medical Director, MD
- RECRUITINGPhase 3NCT06926491Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）Kyowa Kirin Co., Ltd. · PI: Yu Sato
- ACTIVE NOT RECRUITINGPhase 2NCT06433557A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaAscendis Pharma Growth Disorders A/S · PI: Medical Director, MD
- RECRUITINGPhase 2NCT06079398A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaAscendis Pharma A/S · PI: Medical Director, MD
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT05929807A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With AchondroplasiaAscendis Pharma Growth Disorders A/S · PI: Claus Strange
- RECRUITINGNCT06168201VIrtual STudy in Achondroplasia for the US (VISTA)BioMarin Pharmaceutical · PI: Medical Director, MD
- ENROLLING BY INVITATIONPhase 2NCT05145010Extension Study of Infigratinib in Children With Achondroplasia (ACH)QED Therapeutics, a BridgeBio company · PI: QED Therapeutics SVP, Clinical Development
- RECRUITINGNCT05328050Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- ACTIVE NOT RECRUITINGPhase 2NCT04554940A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With AchondroplasiaBioMarin Pharmaceutical · PI: Medical Director, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03989947An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaBioMarin Pharmaceutical · PI: Medical Director MD
- ACTIVE NOT RECRUITINGPhase 3NCT03424018An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaBioMarin Pharmaceutical
- RECRUITINGNCT02597881Achondroplasia Natural History Multicenter Clinical StudyJohns Hopkins University · PI: Julie Hoover-Fong, MD,PhD
- ACTIVE NOT RECRUITINGPhase 2NCT02724228A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)BioMarin Pharmaceutical · PI: Medical Director, MD